Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients. - Santacana Juncosa E; Padullés Zamora A; Colom Codina H; Rodríguez Alonso L; Guardiola Capo J; Bas Minguet J; Padullés Zamora N (Revista espanola de enfermedades digestivas, 2016)